Immune responses generated by intramuscular DNA immunization of Brugia malayi transglutaminase (BmTGA) in mice

Parasitology ◽  
2009 ◽  
Vol 136 (8) ◽  
pp. 887-894 ◽  
Author(s):  
UMA VANAM ◽  
PRINCE R. PRABHU ◽  
VIVEK PANDEY ◽  
GAJALAKSHMI DAKSHINAMURTHY ◽  
MARYADA VENKATA RAMI REDDY ◽  
...  

SUMMARYAn attempt was made to evaluate the immunoprophylactic efficacy of Brugia malayi transglutaminase (BmTGA) as a DNA vaccine, for human lymphatic filariasis. BmTGA was cloned and characterized in the DNA vaccine vector pVAX1. Further, the tissue distribution study of the DNA construct, pVAX-TGA was carried out in mice and the DNA vaccine was shown to be efficiently distributed to all the organs, was accessible to the immune system, and at the same time was metabolized quickly and did not pose problems of toxicity. Intramuscular immunization in mice showed significant antibody production and splenocyte proliferation upon antigenic stimulation. The immune responses were biased towards the Th1 arm, as evaluated in terms of isotype antibody distribution and cytokine profile. Thus, analysis of the humoral and cellular immune responses indicated that BmTGA is a potent immunogen. However, protection studies as determined by the micropore chamber method using live microfilarial larvae, showed that the DNA vaccine could confer only partial protection in the mouse model. We conclude that despite the induction of sufficient humoral and cellular immune responses, BmTGA as a DNA vaccine could not confer much protection against subsequent challenge and other aspects of the immune responses need to be further investigated.

Vaccine ◽  
2016 ◽  
Vol 34 (32) ◽  
pp. 3634-3640 ◽  
Author(s):  
Marie Borggren ◽  
Jens Nielsen ◽  
Ingrid Karlsson ◽  
Tina S. Dalgaard ◽  
Ramona Trebbien ◽  
...  

Vaccine ◽  
2008 ◽  
Vol 26 (49) ◽  
pp. 6225-6231 ◽  
Author(s):  
Krystle A. Lang ◽  
Jian Yan ◽  
Ruxandra Draghia-Akli ◽  
Amir Khan ◽  
David B. Weiner

Vaccine ◽  
2005 ◽  
Vol 23 (14) ◽  
pp. 1649-1656 ◽  
Author(s):  
He Xiao-wen ◽  
Sun Shu-han ◽  
Hu Zhen-lin ◽  
Li Jun ◽  
Jiang Lei ◽  
...  

2017 ◽  
Vol 27 (3) ◽  
pp. 168-174 ◽  
Author(s):  
Yu Yang ◽  
Zhiqiang Shao ◽  
Jiangping Gao

To improve the lower immune intensity of DNA vaccines, we developed a DNA vaccine based on prostate cancer-specific antigen (PSA), which has been suggested as a potential target for prostate cancer therapy, and enhanced the DNA vaccine potency using interleukin-12 (IL-12) as an intramolecular adjuvant. A series of DNA plasmids encoding human PSA, IL-12, and their conjugates was constructed and injected into female mice intramuscularly, followed by an electric pulse. The humoral and cellular immune responses after immunization were detected by ELISA and ELISPOT, respectively. To evaluate the therapeutic efficacy of these plasmids, a mouse model with a PSA-expressing tumor was constructed. Mice vaccinated with PSA-IL-12 plasmids elicited the strongest PSA-specific humoral and cellular immune responses. Furthermore, these vaccinations inhibited the growth of PSA-expressing tumors and prolonged mouse survival. These observations emphasize the potential of the IL-12 gene as an intramolecular adjuvant for DNA vaccines. Moreover, the vaccine based on PSA and IL-12 may be a promising treatment for prostate cancer.


2004 ◽  
Vol 23 (5) ◽  
pp. 335-339 ◽  
Author(s):  
Hongxuan He ◽  
Baohua Zhao ◽  
Liyan Liu ◽  
Kai Zhou ◽  
Ximing Qin ◽  
...  

2014 ◽  
Vol 10 (8) ◽  
pp. 2357-2365 ◽  
Author(s):  
Brian Latimer ◽  
Roberta Toporovski ◽  
Jian Yan ◽  
Panyupa Pankhong ◽  
Matthew P Morrow ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document